

Model-free predictions in personalized medicine with quantified uncertainty and personalized decisions: A case study on the conversion from MCI to AD

P.G.L. Porta Mana^{1,2,*}, Ingrid Rye³, Alexandra Vik^{1,2}, Marek Kocinski^{2,4},
Arvid Lundervold^{2,4}, Astri J. Lundervold³, and Alexander S. Lundervold^{1,2}

¹*Department of Computer Science, Electrical Engineering and Mathematical Sciences, Western Norway University of Applied Sciences, Bergen, Norway*

²*Mohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University Hospital, Bergen, Norway*

³*Department of Biological and Medical Psychology, University of Bergen, Norway*

⁴*Department of Biomedicine, University of Bergen, Norway*

Correspondence*:
Corresponding Author
pgl@portamana.org

2 ABSTRACT

3 [Luca & Astri, draft]

4 Patients with Mild Cognitive Impairment have an increased risk of Alzheimer's disease. Early
5 identification of underlying neurodegenerative processes is essential to provide treatment before
6 the disease is well established in the brain. It is therefore of extreme interest to study how well
7 several kinds of predictors – from neuropsychological examinations to advanced brain-imaging
8 techniques – allow us to prognose the onset of the disease.

9 But more is needed for a personalized approach to prognosis, prevention, treatment, than just
10 the obvious requirement that prognoses be as best as they can be for each patient. Several
11 situational elements that can be different from patient to patient must be accounted for:

- 12 • the *kinds* of clinical data and evidence available for prognosis;
- 13 • the *outcomes* of the same kind of clinical data and evidence;
- 14 • the kinds of treatment or prevention strategies available, owing to different attitudes toward
15 life, different family networks and possibilities of familial support, different additional medical
16 factors such as physical disabilities, different economic means;
- 17 • the advantages and disadvantages, benefits and costs of the same kinds of treatment or
18 prevention strategies; the patient has a major role in the quantification of such benefits and
19 costs;
- 20 • finally, the initial evaluation by the clinician – which often relies on too subtle clues (family
21 history, regional history, previous case experience) to be considered as measurable data.

22 Statistical decision theory is the normative quantification framework that takes into account these
23 fundamental differences. Medicine has the distinction of having been one of the first fields to
24 adopt this framework, exemplified in brilliant old and new textbooks on clinical decision making.

25 Clinical decision making makes allowance for these differences among patients through two
26 requirements. First, the quantification of prognostic evidence on one side, and of benefits and
27 costs of treatments and prevention strategies on the other, must be clearly separated and handled
28 in a modular way. Two patients can have the same prognostic evidence, and yet very different
29 prevention options. Second, the quantification of independent prognostic evidence ought to be in
30 the form of *likelihoods about the health condition* (or equivalently of likelihood ratios, in a binary
31 case), that is, of the probabilities of the observed test outcomes given the hypothesized health
32 conditions. Likelihoods from independent clinical tests and predictors can then be combined
33 with a simple multiplication; for one patient we could have three kinds of predictor available; for
34 another, we could have five. The clinician's pre-test assessment is included in the form of a
35 probability. These patient-dependent probabilities are combined with the patient-dependent costs
36 and benefits of treatment or prevention, to arrive at the best course of action for that patient. The
37 main result underlying statistical decision theory is that decision making *must* take this particular
38 mathematical form in order to be optimal and logically consistent.

39 The present work investigates the prognostic power of a set of neuropsychological and Magnetic
40 Resonance Imaging examinations, demographic data, and genetic information about APOE status,
41 for the prediction of the onset of Alzheimer's disease in patients defined as mildly cognitively
42 impaired at a baseline examination. The longitudinal data used come from the ADNI database.

43 The prognostic power of these predictors is quantified in the form of a combined likelihood for
44 the onset of Alzheimer's disease. As a hypothetical example application of personalized clinical
45 decision making, three patient cases are considered where a clinician starts with prognostic
46 uncertainties, possibly coming from other tests, of 50%/50%, 25%/75%, 75%/25%. It is shown
47 how these pre-test probabilities are changed by the predictors.

48 This quantification also allows us to rank the relative prognostic power of the predictors. It is
49 found that several neuropsychological examinations have highest prognostic power, much higher
50 than the genetic and an imaging-derived predictors included in the present set.

51 Several additional advantages of this quantification framework are also exemplified and
52 discussed in the present work:

- 53 • missing data are automatically handled, and results having partial data are not discarded; this
54 quantification therefore also accounts for patient-dependent availability of *non-independent*
55 predictors;
- 56 • no modelling assumptions (e.g. linearity, gaussianity, functional dependence) are made;
- 57 • the prognostic power obtained is intrinsic to the predictors, that is, it is a bound for *any*
58 prognostic algorithm;
- 59 • variability ranges of the results owing to the finite size of the sample data is automatically
60 quantified.
- 61 • the values obtained, being probabilities, are more easily interpretable than scores of various
62 kinds.

63  Maybe we can also add two examples of different clinical decisions, coming from different
64 benefit/cost evaluations?

65 For full guidelines regarding your manuscript please refer to Author Guidelines.

66 As a primary goal, the abstract should render the general significance and conceptual advance of the work clearly
67 accessible to a broad readership. References should not be cited in the abstract. Leave the Abstract empty if your
68 article does not require one, please see Summary Table for details according to article type.


69 **Keywords:** keyword, keyword, keyword, keyword, keyword, keyword, keyword, keyword


1 INTRODUCTION

70 [Luca, pieces of text]

71 Personalized diagnosis, prognosis, treatment, and prevention strategies must make allowance for several
72 fundamental differences among patients:

- 73 • the *kinds* of clinical data and evidence available for diagnosis or prognosis can be different;
- 74 • the *values* of the same kind of clinical data and evidence can be different;
- 75 • the kinds of treatment or prevention options can be different;
- 76 • the advantages and disadvantages, benefits and costs of the same kinds of treatment or prevention can
77 be different;
- 78 • finally, the evaluation of the clinician – which often relies on too subtle clues (family history, regional
79 history, case experience) to be considered as measurable data – can be different.

80 Is there really a methodological framework that can take all these differences into account? Yes, there
81 is, and Medicine has the distinction of having been one of the first fields to adopt it (Ledley and Lusted,
82 1959): Statistical Decision Theory. Its application in Medicine is explained and exemplified in several,
83 brilliant, old and new textbooks (Weinstein and Fineberg, 1980; Sox et al., 2013; Hunink et al., 2014). This
84 theory has mathematical and logical foundations and its principles constitute indeed the foundations for the
85 definition and realization of Artificial Intelligence (Russell and Norvig, 2022) 

86 The basics of clinical decision making  ..basics: each piece of evidence contributes with a likelihood or
87 odds; they combine together and together with the clinician's pre-data evaluation. Then they are combined
88 with the different benefits/costs of treatments or prevention strategies to find the optimal one. Decision
89 trees can be necessary (but don't change this framework). Costs & benefits are evaluated by clinician &
90 patient together.

$$\begin{aligned}
 & \overbrace{p(\text{health condition} \mid \text{results of all tests, prior info})}^{\text{post-test probability}} \propto \\
 & \overbrace{p(\text{health condition} \mid \text{prior info})}^{\text{pre-test probability by clinician}} \times \\
 & \underbrace{\left\{ \begin{array}{l} p(\text{result of 1st test} \mid \text{health condition, prior info}) \times \\ p(\text{result of 2nd test} \mid \text{health condition, prior info}) \times \\ \dots \end{array} \right\}}_{\text{likelihoods of tests}} \quad (1)
 \end{aligned}$$

91 For Original Research Articles (Name et al., 1996), Clinical Trial Articles (LastName1 et al., 2013), and Technology Reports
 92 (Surname1, 2010), the introduction should be succinct, with no subheadings (Name, 1993). For Case Reports the Introduction
 93 should include symptoms at presentation (Surname, 2002), physical exams and lab results (LastName1 et al., 2011).

2 ARTICLE TYPES

94 For requirements for a specific article type please refer to the Article Types on any Frontiers journal page.
 95 Please also refer to Author Guidelines for further information on how to organize your manuscript in the
 96 required sections or their equivalents for your field

3 MANUSCRIPT FORMATTING

97 3.1 Heading Levels

98 3.2 Level 2

99 3.2.1 Level 3

100 3.2.1.1 Level 4

101 3.2.1.1.1 Level 5

102 3.3 Equations

103 Equations should be inserted in editable format from the equation editor.

$$\sum x + y = Z \quad (2)$$

104 3.4 Figures

105 Frontiers requires figures to be submitted individually, in the same order as they are referred to in the
 106 manuscript. Figures will then be automatically embedded at the bottom of the submitted manuscript. Kindly
 107 ensure that each table and figure is mentioned in the text and in numerical order. Figures must be of
 108 sufficient resolution for publication see here for examples and minimum requirements. Figures which are

not according to the guidelines will cause substantial delay during the production process. Please see here for full figure guidelines. Cite figures with subfigures as figure 2a and 2b.

3.4.1 Permission to Reuse and Copyright

Figures, tables, and images will be published under a Creative Commons CC-BY licence and permission must be obtained for use of copyrighted material from other sources (including re-published/adapted/modified/partial figures and images from the internet). It is the responsibility of the authors to acquire the licenses, to follow any citation instructions requested by third-party rights holders, and cover any supplementary charges.

3.5 Tables

Tables should be inserted at the end of the manuscript. Please build your table directly in LaTeX. Tables provided as jpeg/tiff files will not be accepted. Please note that very large tables (covering several pages) cannot be included in the final PDF for reasons of space. These tables will be published as Supplementary Material on the online article page at the time of acceptance. The author will be notified during the typesetting of the final article if this is the case.

4 NOMENCLATURE

4.1 Resource Identification Initiative

To take part in the Resource Identification Initiative, please use the corresponding catalog number and RRID in your current manuscript. For more information about the project and for steps on how to search for an RRID, please click here.

4.2 Life Science Identifiers

Life Science Identifiers (LSIDs) for ZOOBANK registered names or nomenclatural acts should be listed in the manuscript before the keywords. For more information on LSIDs please see Inclusion of Zoological Nomenclature section of the guidelines.

5 ADDITIONAL REQUIREMENTS

For additional requirements for specific article types and further information please refer to Author Guidelines.

CONFLICT OF INTEREST STATEMENT

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

AUTHOR CONTRIBUTIONS

The Author Contributions section is mandatory for all articles, including articles by sole authors. If an appropriate statement is not provided on submission, a standard one will be inserted during the production process. The Author Contributions statement must describe the contributions of individual authors referred

138 to by their initials and, in doing so, all authors agree to be accountable for the content of the work. Please
139 see here for full authorship criteria.

FUNDING

140 Details of all funding sources should be provided, including grant numbers if applicable. Please ensure to
141 add all necessary funding information, as after publication this is no longer possible.

ACKNOWLEDGMENTS

142 This is a short text to acknowledge the contributions of specific colleagues, institutions, or agencies that
143 aided the efforts of the authors.

SUPPLEMENTAL DATA

144 Supplementary Material should be uploaded separately on submission, if there are Supplementary Figures,
145 please include the caption in the same file as the figure. LaTeX Supplementary Material templates can be
146 found in the Frontiers LaTeX folder.

DATA AVAILABILITY STATEMENT

147 The datasets [GENERATED/ANALYZED] for this study can be found in the [NAME OF REPOSITORY]
148 [LINK].

REFERENCES

- 149 Hunink, M. G. M., Weinstein, M. C., Wittenberg, E., Drummond, M. F., Pliskin, J. S., Wong, J. B.,
150 et al. (2014). *Decision Making in Health and Medicine: Integrating Evidence and Values* (Cambridge:
151 Cambridge University Press), 2 edn. doi:10.1017/CBO9781139506779. First publ. 2001
152 [Dataset] LastName1, A., LastName2, A., and LastName3, A. (2011). Data title. doi:10.000/55555
153 LastName1, A., LastName2, A., and LastName3, A. (2013). Article title. *Frontiers in Neuroscience* 30,
154 10127–10134. doi:10.3389/fnins.2013.12345
155 Ledley, R. S. and Lusted, L. B. (1959). Reasoning foundations of medical diagnosis: Symbolic logic,
156 probability, and value theory aid our understanding of how physicians reason. *Science* 130, 9–21.
157 doi:10.1126/science.130.3366.9
158 Name, A. (1993). *The title of the work* (The city: The name of the publisher)
159 Name, C., Surname, D., and LastName, F. (1996). The title of the work. In *The title of the conference*
160 *proceedings*, eds. E. Name1 and E. Name2 (The name of the publisher), 41–50
161 Russell, S. J. and Norvig, P. (2022). *Artificial Intelligence: A Modern Approach*. Pearson
162 series in artificial intelligence (Harlow, UK: Pearson), fourth global ed. edn. [http:](http://aima.cs.berkeley.edu/global-index.html)
163 [//aima.cs.berkeley.edu/global-index.html](http://aima.cs.berkeley.edu/global-index.html), [https://archive.org/](https://archive.org/details/artificial-intelligence-a-modern-approach-4th-edition)
164 [details/artificial-intelligence-a-modern-approach-4th-edition](https://archive.org/details/artificial-intelligence-a-modern-approach-4th-edition). First
165 publ. 1995
166 Sox, H. C., Higgins, M. C., and Owens, D. K. (2013). *Medical Decision Making* (New York: Wiley), 2 edn.
167 doi:10.1002/9781118341544. First publ. 1988
168 Surname, B. (2002). The title of the work. In *The title of the book*, ed. E. Name (The city: The name of the
169 publisher). 201–213

- 170 Surname1, H. (2010). *The title of the work* (Patent country: Patent number)
- 171 Weinstein, M. C. and Fineberg, H. V. (1980). *Clinical Decision Analysis* (Philadelphia: Saunders)

FIGURE CAPTIONS



Figure 1. Enter the caption for your figure here. Repeat as necessary for each of your figures



Figure 2a. This is Subfigure 1.



Figure 2b. This is Subfigure 2.

Figure 2. Enter the caption for your subfigure here. **(A)** This is the caption for Subfigure 1. **(B)** This is the caption for Subfigure 2.